Skip to main content

ADVERTISEMENT

comparative effectiveness

What is the Standard First-Line Therapy for Advanced HCC?
Quiz
12/01/2020
Journal of Clinical Pathways
News
07/01/2020
A minimally invasive procedure is as effective as surgery for treating early-stage kidney cancer, according to 10-year survival data published in Radiology (online June 9, 2020;...
A minimally invasive procedure is as effective as surgery for treating early-stage kidney cancer, according to 10-year survival data published in Radiology (online June 9, 2020;...
A...
07/01/2020
Journal of Clinical Pathways
News
06/23/2020
Among patients with early-stage cervical cancer, minimally invasive radical hysterectomy is associated with an elevated risk of recurrence and death compared with open radical hysterectomy, according to a recent...
Among patients with early-stage cervical cancer, minimally invasive radical hysterectomy is associated with an elevated risk of recurrence and death compared with open radical hysterectomy, according to a recent...
Among...
06/23/2020
Journal of Clinical Pathways
News
06/03/2020
Compared with two rituximab-containing regimens, acalabrutinib significantly improves progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL) and has a comparable safety profile to these...
Compared with two rituximab-containing regimens, acalabrutinib significantly improves progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL) and has a comparable safety profile to these...
...
06/03/2020
Journal of Clinical Pathways
News
05/21/2020
Venetoclax plus low-dose cytarabine offers a clinically meaningful improvement in survival compared with placebo plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML),...
Venetoclax plus low-dose cytarabine offers a clinically meaningful improvement in survival compared with placebo plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML),...
...
05/21/2020
Journal of Clinical Pathways
Rapid Communication
11/30/2019
Leah Griffin
Marissa J. Carter
Ralph D’Agostino
Lucy D’Agostino McGowan
This comparative effectiveness study evaluates the value proposition of 2 collagen-containing wound dressings — oxidized regenerated cellulose (ORC)/collagen/silver-ORC dressing and ovine collagen extracellular matrix (ECM) — in matched...
This comparative effectiveness study evaluates the value proposition of 2 collagen-containing wound dressings — oxidized regenerated cellulose (ORC)/collagen/silver-ORC dressing and ovine collagen extracellular matrix (ECM) — in matched...
This comparative effectiveness...
11/30/2019
Wounds
News
08/22/2017
JCP Editors
A recent comparative effectiveness study examined long-term survival outcomes for patients with multiple stages of breast cancer after undergoing either mastectomy or breast-conserving surgery, published in the...
A recent comparative effectiveness study examined long-term survival outcomes for patients with multiple stages of breast cancer after undergoing either mastectomy or breast-conserving surgery, published in the...
A...
08/22/2017
Journal of Clinical Pathways
Research in Review
08/18/2017
JCP Editors
A recent study uncovered the benefits of adding high-intensity local treatment to systemic therapy for head and neck squamous cell carcinoma, published in Cancer (online August 17, 2017;...
A recent study uncovered the benefits of adding high-intensity local treatment to systemic therapy for head and neck squamous cell carcinoma, published in Cancer (online August 17, 2017;...
A...
08/18/2017
Journal of Clinical Pathways
Research in Review
08/18/2017
JCP Editors
A recent study compared the treatment effects and adverse events of first-line chemotherapy regimens in patients with treatment-naïve diffuse large B-cell lymphoma (DLBCL). Rituximab plus cyclophosphamide,...
A recent study compared the treatment effects and adverse events of first-line chemotherapy regimens in patients with treatment-naïve diffuse large B-cell lymphoma (DLBCL). Rituximab plus cyclophosphamide,...
A...
08/18/2017
Journal of Clinical Pathways